NCM·Healthcare·$79M·#105 / 520 in Healthcare
ICCC ImmuCell Corporation
63SOLID
CATEGORY BREAKDOWN
GROWTH7
QUALITY48
STABILITY85
VALUATION91
GOVERNANCE100
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+4.3%
7
> 50% strong
Gross Margin
Revenue retained after direct costs
41.4%
57
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
48.8%
56
< 25% strong
Price / Sales
Market cap relative to trailing revenue
2.8x
91
< 3x strong
Rule of 40
Growth rate plus operating margin
10
35
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
32.1%
100
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+0.0%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE ICCC WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when ICCC's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.